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Abstract
Inhibiting the interaction between ß-amyloid (Aß) and a neuronal cell surface receptor, LilrB2, has 
been suggested as a potential route for treating Alzheimer’s disease (AD). Supporting this 
approach, AD-like symptoms are reduced in mouse models following genetic depletion of the 
LilrB2 homolog. In its pathogenic, oligomeric state, Aß binds to LilrB2, triggering a pathway to 
synaptic loss. Here we identified the LilrB2 binding moieties of Aß (16KLVFFA21) and identified 
its binding site on LilrB2 from a crystal structure of LilrB2 immunoglobulin domains D1D2 
complexed to small molecules that mimic phenylalanine residues. In this structure, we observed 
two pockets that can accommodate the phenylalanine sidechains of KLVFFA. These pockets were 
confirmed to be 16KLVFFA21 binding sites by mutagenesis. Rosetta docking revealed a plausible 
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geometry for the Aß-LilrB2 complex and assisted with the structure-guided selection of small 
molecule inhibitors. These molecules inhibit Aß-LilrB2 interactions in vitro and on the cell surface 
and reduce Aß cytotoxicity, which suggests these inhibitors are potential therapeutic leads against 
AD.
Graphical Abstract
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INTRODUCTION
Aggregated ß-amyloid (Aß) is found in large amounts in the autopsied brains of Alzheimer’s 
Disease (AD) patients, and it is widely considered as a key factor in triggering neural 
degeneration in AD1,2. The longstanding amyloid cascade hypothesis has been challenged in 
recent years by the lack of correlation between Aß accumulation and cognitive impairment 
in elderly patients and the better correlation between histopathological changes of 
neurofibrillary tangles (aggregation of tau) and loss of cognition3–5. However, three major 
findings continue to support the hypothesis: Aß overproduction is found in nearly all familial 
forms of AD6,7, the oligomeric form of Aß is toxic to neurons8–10, and overexpression of Aß 
and APP (amyloid precursor protein) mutants in animal models leads to the development of 
AD related phenotypes11,12. Recent AD related studies continue to support the key role of 
Aß13,14.
Extensive work has focused on developing inhibitors of Aß toxicity as potential therapeutic 
drugs for AD. Most of these target Aß aggregation (e.g.15–17), reduce the production of Aß 
through inhibition of ß or γ-secretase (e.g.18–20), or reduce Aß levels through 
immunotherapy21 (e.g.22). Recent studies suggest that one or more high-affinity protein 
receptors on the neuronal cell surface, such as cellular prion protein (PrPC 23) and ephrin 
type B receptor 2 (EphB2 24), are responsible for the recruitment of Aß oligomers and 
subsequent neurotoxicity25. These findings have sparked interest in illuminating the 
molecular mechanism of Aß-receptor recognition, with the hope that this information will 
lead to the development of new, effective AD therapeutics that inhibit the interaction of Aß 
with neuron cell receptors.
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Among all these cell surface Aß receptors25, LilrB2 is one of a few receptors that are 
reported to be promising therapeutic targets for treatment of AD, based on the observation 
that genetic depletion of the murine homolog, PirB (PirB−/−), rescues Aß induced AD-
related phenotypes in multiple model systems from cultured cortical neurons to transgenic 
mice, including recognition memory defects in APP/PS1 mice26. The two amino-terminal 
extracellular immunoglobulin domains (D1D2) of LilrB2 and its murine homolog PirB 
selectively bind Aß oligomers with nanomolar affinity. LilrB2 protein is detected in human 
brains of both AD patients and non-AD adults, with no significant difference in expression 
level, but its downstream signaling is altered in AD brains, implicating LilrB2 in Aß-
dependent synaptic loss26. Here we identify the binding moieties of both Aß oligomers and 
LilrB2 and present a model for their interaction. Based on the structural model, we designed 
Aß-LilrB2 interaction inhibitors by computationally selecting molecules to compete with Aß 
for the LilrB2 binding sites. The resulting compounds inhibited the interaction between 
oligomeric Aß and LilrB2 with up to high nanomolar Ki and low micromolar IC50 values. 
They also showed the ability to inhibit LilrB2 induced Aß-cell contact, and therefore to 
inhibit Aß cytotoxicity.
RESULTS
Mapping the core region of Aβ binding to the LilrB2 D1D2 domains
A 200-residue recombinant LilrB2 segment spanning the D1 and D2 domains (LilrB2 
D1D2) was used in our study, and oligomeric human Aß1–42 (Aß42) was prepared by 
incubating 10 μM Aß42 at 37 °C overnight (Supplementary Fig. 1). LilrB2 D1D2 selectively 
binds oligomeric Aß42 as previously reported26 (Supplementary Fig. 2). To map the binding 
core of Aß, we developed an ELISA-based interaction assay that enables high-throughput 
detection of the Aß-LilrB2 interaction. We immobilized LilrB2 D1D2 on an ELISA plate 
and measured the amount of bound Aß segments by Aß specific antibodies or the 
fluorescence signal of fluorescein conjugated to the segments. We found the LilrB2 D1D2 
domains bind to Aß42 and its amino-terminal moiety Aß1–21, but not to Aß1–15 (Fig. 1 and 
Supplementary Table 1). We also found that the LilrB2 D1D2 domains bind to Aß15–35 but 
not Aß22–42 (Supplementary Fig. 2). These results indicate that the Aß segment 
16KLVFFA21, which is also widely considered as a key element of Aß aggregation27,28, is 
the core region that binds to LilrB2 D1D2.
We then tested the interaction of LilrB2 D1D2 with 16KLVFFA21 derived peptides. We did 
not detect binding of LilrB2 D1D2 to the peptide that contains a single copy of 16KLVFFA21 
(Aß16–21, Fig. 1). However, our experiment showed it did bind to a tandem repeat design of 
16KLVFFA21 (Aß16–21-TR, sequence KLVFFAPDGKLVFFA, Fig. 1, Supplementary Table 
1). The binding we observed with the tandem repeats was not due to introduction of the Pro-
Asp-Gly linker between the two 16KLVFFA21 copies, since the control peptide with a single 
copy of 16KLVFFA21 and the linker (Aß16–21-C, sequence KLVFFAPDG) did not bind to 
LilrB2 D1D2 (Fig. 1). These results suggest that two copies of 16KLVFFA21 represent a 
minimal Aß oligomer and the core epitope for LilrB2 binding. Moreover, the observation 
that the tandem repeat but not the single copy of 16KLVFFA21 binds to LilrB2 suggests that 
LilrB2 recognizes a particular conformation in addition to the primary amino acid sequence. 
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We hypothesize that the antiparallel dimer of 16KLVFFA21, rather than a single copy, readily 
assembles into a minimal oligomer, reasoning that the tandem linkage lowers the entropy 
barrier to oligomer formation (see discussion).
Crystal structure of LilrB2 D1D2 complexed with benzamidine
We mixed LilrB2 D1D2 with various Aß segments and screened for crystals, and we 
determined the crystal structure of LilrB2 D1D2 mixed with Aß14–23 at 2.1 Å resolution 
(Supplementary Table 2). In this structure, no density for the Aß segment was found, which 
is consistent with no detectable binding of 16KLVFFA21 monomer to LilrB2 D1D2. Instead 
we found four benzamidine (Ben) molecules (Fig. 2a) which were used as an additive for 
crystal optimization. The presence and positions of the benzamidine molecules were 
determined by inspection of difference electron density maps (Fo-Fc, Supplementary Fig. 3) 
and the surrounding environment (Fig. 2b and c). The chemical structure of benzamidine is 
similar to that of phenylalanine (Fig. 2a), so it mimics the binding of phenylalanine from the 
16KLVFFA21 binding core of Aß. We chose the binding pockets of Ben 3 and 4 for further 
investigation because of the following observations: First, the binding pockets of Ben 3 and 
4 are close to each other (separated by 7.5 Å) and are both located in the groove between D1 
and D2 domains (Fig. 2a). Given that at least two copies of 16KLVFFA21 are required to 
bind to LilrB2 (Fig. 1) and each copy has two phenylalanines, it is likely that the binding 
sites for 16KLVFFA21 on LilrB2 have two phenylalanine binding pockets close to each other. 
Second, most residues comprising the Ben 3 and 4 binding pockets are hydrophobic with 
geometry suitable for binding bulky hydrophobic residues such as phenylalanine (Ile154, 
Tyr199, Pro204, Tyr 205 and Trp207for Ben 3 and Val38, Cys156, Pro164, Cys166 and Trp207 for 
Ben 4) (Fig. 2a, b and c). Hydrogen bonding (Ben 3 with Gly51 and Asn168; Ben 4 with 
Asp36) and crystal lattice contacts (Ben 3 with Gly51 and Ben 4 with Leu53) also stabilize 
benzamidine binding, but are minor contributors and appear unnecessary for binding 
phenylalanine. Third, Asp36 and other negatively charged residues are located adjacent to the 
groove (Supplementary Fig. 3), close enough to neutralize the positive charge of Lys16 of 
16KLVFFA21 and further stabilize its binding. Fourth, by superimposing our complex on the 
ligand free LilrB2 D1D2 structure (PDB ID 2GW529), we found that upon ligand binding, 
the binding groove widens due to movement of ß-strand of residues 165 to 168. In addition, 
the loop composed of residues 159 to 164, which is disordered and lacking electron density 
in the ligand-free structure, becomes ordered and forms a protective cap over the binding 
groove (Supplementary Fig. 3). These slight conformational changes make this groove a 
better binding site for both benzamidine and presumably the Aß binding core. On the basis 
of this structural analysis, we hypothesized that the binding pockets of Ben 3 and 4 on 
LilrB2 are the binding sites for 16KLVFFA21 of Aß; in the following we provide support for 
this hypothesis by mutagenesis and Rosetta docking.
Validation of the binding sites of LilrB2 by mutagenesis and Rosetta docking
We designed three LilrB2 mutations to validate the putative binding sites for Aß. We first 
chose Asn168 and Val38, whose side chains participate in the Ben 3 and 4 pockets 
respectively (Fig. 2b & c). We mutated both to tryptophan to block these two pockets by 
creating steric hindrance with the ligands (Supplementary Fig. 3). We also designed the 
D36G mutation to target Asp36 that putatively neutralizes the negative charge of Lys16 of 
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Aß. The three resulting mutant proteins, LilrB2 D1D2 D36G, V38W and N168W, bound 
significantly lower amounts of full length Aß as well as the 16KLVFFA21 tandem repeat 
(Aß16–21-TR) compared to wildtype at the same loading concentration in ELISA-based 
interaction assays (Fig. 3a and Supplementary Fig. 4). Size exclusion chromatography shows 
that all three mutants elute at the same retention volume as wild type (Supplementary Fig. 
4), and 1H-15N-HSQC spectra show that these mutants have similar chemical shift patterns 
as wildtype (Supplementary Fig. 4), which indicates that diminished strength of these 
interactions is not due to changes in overall folding or the aggregation state of LilrB2. These 
results indicate that blocking Ben 3 and 4 binding pockets by single mutations diminishes 
the binding of LilrB2 for both full length Aß and the 16KLVFFA21 tandem repeat. Therefore, 
these results support our hypothesis that Ben 3 and 4 binding pockets are the binding sites 
for 16KLVFFA21 in the tandem repeat and in full length Aß.
To further validate the binding sites on LilrB2 and to develop a model of Aß-LilrB2 
interaction, we applied Rosetta flexible peptide docking30 to dock the 16KLVFFA21 segment 
to LilrB2 D1D2. We used our crystal structure shown in Fig. 2 as a starting model of LilrB2. 
An antiparallel ß-sheet unit was taken from the crystal structure of the 16KLVFFA21 steric 
zipper (PDB ID 3OW928), in order to represent a minimal ß-sheet conformation of 
oligomeric Aß31, and the tandem repeat of Aß 16–21-TR (see discussion). During docking 
simulations, we confined KLVFFA to contact three key residues (Asp36, Val38, Asn168) that 
we identified as important for Aβ binding in our mutagenesis experiments. To minimize the 
influence of the starting orientation of the peptide, we placed two strands of KLVFFA away 
from the groove between the D1 and D2 domains (putative binding site) in a random 
orientation. Notably, we imposed no restraints to occupy the putative binding pockets 
identified in our crystal structure with benzamidine. For each starting conformation, 50,000 
models were generated and the top 500 models with favorable Rosetta energies were further 
refined by energy optimization. After refinement, the five models ranked by Rosetta 
energies32 and shape complementary33 were selected for visual inspection. We found one 
model with two phenylalanine residues located within the binding pockets of Ben 3 and 4 
(Fig. 3b to d). In this model, two independent KLVFFA molecules associated as an anti-
parallel ß-sheet and docked in the groove between D1 and D2. Phe20 and Phe19 from 
separate molecules docked in the pockets of Ben 3 and 4, respectively. The RMSD of the 
aromatic rings between phenylalanine residues and benzamidine molecules are 2.3 Å. These 
docking results support our prediction of LilrB2 binding sites and provide a putative model 
of Aß-LilrB2 interaction. No other plausible Aß conformation was generated by our 
computational docking that fits two phenylalanines in these putative LilrB2 binding sites.
Structure-based design of Aβ-LilrB2 interaction inhibitors
We designed Aß-LilrB2 interaction inhibitors (ALI) to occupy the binding sites on LilrB2 
and prevent Aß binding, as directed by our structural model of the Aß-LilrB2 complex. Our 
approach, adapted from previous work34, combines knowledge of amyloid structures and 
computational screening to discover small molecules that interact with Aß fibrils and protect 
cells against their toxicity. We searched a compound library of ~32,000 small molecules, 
including approved drugs, drugs in animal tests and clinical trials, and natural products 
whose pharmacokinetic (PK) and/or toxicity profile is known (Supplementary Fig. 5 and 
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Supplementary method). Small molecules that can potentially mimic the conformation of the 
aromatic rings of the ligand in our crystal structure were selected and docked to the binding 
pocket of LilrB2. The compounds were then ranked by their predicted binding energy and 
the similarity between the docked model and the crystal structure. Finally, 12 top-ranking 
small molecules (ALI 1–12) were chosen for experimental characterization based on their 
shape similarity, computational docking energy, and potential to cross the blood-brain 
barrier (Supplementary Table 3).
We tested the inhibitory efficiency of all candidates by quantitative immunoprecipitation 
assays with LilrB2 D1D2 and oligomeric Aß42. At a molar ratio of 1:10:50 
(LilrB2:Aß:inhibitor), 9 out of 12 candidates show inhibition of Aß-LilrB2 interaction with a 
lower Aß binding signal that considered to be statistically significant compared to the 
controls with no inhibitor added (Fig. 4a). Six candidates (ALI4, 5, 6, 7, 9 and 10) were 
selected for concentration dependent studies, and all of them inhibited Aß-LilrB2 interaction 
in a dose-dependent manner (Fig. 4b and Supplementary Fig. 6). Their docking models 
created by high resolution Rosetta docking are superimposed with benzamidine and are 
shown in Fig. 4c and Supplementary Fig. 6. The statistical analysis of the concentration 
dependent studies shows that all 6 candidates have high nanomolar to low micromolar Ki 
and low micromolar IC50 values (Fig. 4d). These results suggest that structure-based design 
was successful in identifying small-molecule inhibitors that block Aß-LilrB2 interaction in 
vitro.
Tests of inhibitors by cell-based assays
To test the inhibitors on cells, we transiently transfected HEK293T cells with full-length 
LilrB2 having monomer red fluorescent protein (mRFP) conjugated at its carboxy-terminus 
(LilrB2-mRFP). We then tested the interaction of LilrB2 with exogenously added oligomeric 
Aß42 conjugated at its amino-terminus with fluorescein (FITC-Aß42, Supplementary Fig. 
7). HEK293T cells transfected with mRFP alone were used as a negative control. After 3 
hours of incubation with FITC-Aß42, we fixed and washed the cells, and found the cells 
transfected with mRFP bind only 13% of FITC-Aß42 relative to cells transfected with 
LilrB2-mRFP (Fig. 5a & b), consistent with previously reported results using HEK293 cells 
expressing LilrB2 or PirB26. These results indicate LilrB2 induces Aß-cell interaction. When 
we added a 10 μM concentration of our inhibitors to cells before adding FITC-Aß42, we 
found the amount of bound Aß42 was significantly reduced; the lowest values are 27% 
(ALI10) and 29% (ALI6) relative to the controls in which no inhibitor was added (Fig. 5a & 
b). These results indicate our selected small molecules inhibit Aß-LilrB2 interaction at the 
cellular level, and therefore inhibit LilrB2 induced Aß-cell contact.
We selected candidate compound ALI6 to examine its effect on the cytotoxicity of Aß, 
because ALI6 exhibits the best score in the computational docking and the best inhibitory 
activity both in vitro and on cell levels. We transfected HEK293T cells with LilrB2-mRFP 
and treated them with 500 nM oligomeric Aß42 for 24 hours. Cell viability (MTT) assays 
showed that 38% of cells were killed relative to controls in which the cells were incubated 
with PBS buffer solutions (Fig. 5c). Further cell viability assays established that ALI6 
rescues the cells in a dose-dependent manner. When the cells were treated with ALI6 5 
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minutes prior to adding Aß42, 1 μM ALI6 reduces the cell death to 30%, 2 μM ALI6 
reduces the cell death to 24%, 5 μM ALI6 reduces the cell death to 8% and 10μM ALI6 
reduces the cell death to 7%. Moreover, 10μM ALI6 in the absence of Aß42 shows no effect 
on cell viability. These results suggest that ALI6 inhibits Aß cytotoxicity.
Validation of ALI6 with primary neurons
Primary neuron models have been widely used to test Aß cytotoxicity and the effect of Aß 
inhibitors, and two known inhibitors of Aß, curcumin35 and (–)-epigallocatechin-3-gallate 
(EGCG)36, have been reported to rescue the neurotoxic effects of Aß. We further validated 
the effect of ALI6 with mouse primary neurons. Cells from cortices dissected at embryonic 
day 15 were dispersed and cultured for 14 days in vitro (DIV14). Mouse cortical neurons 
were previously shown to express PirB at DIV1437. Cells were then treated with 500 nM 
FITC-Aß42 to assess Aß binding. We found that cells pre-treated with 10 μM ALI6 bound 
39.0 ± 20.5% (mean ± SD) of FITC-Aß42 compared to cells pre-treated with the same 
amount of DMSO (Fig. 6a & b), indicating that ALI6 inhibits the binding of Aß to neurons. 
The observation that ALI6 does not fully inhibit Aß binding, even at a higher dose (50 μM 
ALI6, bound 49.9 ± 12.3% FITC-Aß42, Fig. 6b) indicates there are Aß receptors other than 
LilrB2 on the neuronal cell surface, and is consistent with the observation of Aß42 binding 
to neuron cells from PirB−/− mice at 50% the level of wild-type neurons26.
Although the binding of Aß was not fully eliminated, we found that ALI6 is sufficient in 
inhibiting Aß cytotoxicity in primary neurons similar to curcumin35 and EGCG36. Using 
terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) assays to detect 
apoptotic DNA fragmentation, we found 50.1 ± 4.3% of the cells treated with Aß42 and 
DMSO undergo cell death (Fig. 6c & d). When DMSO was substituted with same amount of 
ALI6 (5 μM), cell death dropped to 16.5 ± 8.9%, equivalent to the vehicle control (11.9 
± 11.4%) and ALI6 alone (11.0 ± 11.6%). These results support the potential of ALI6 for 
rescuing Aß caused neuron damage.
We further tested the effect of ALI6 on the downstream pathway of LilrB2. A previous study 
proposed that Aß-LilrB2 interaction causes dephosphorylation of cofilin, an actin-
depolymerizing factor, and leading to eventual synapse loss26. Indeed, the same study 
showed the phosphorylated cofilin (p-cofilin)/total cofilin level decreasing in primary 
neurons treated with Aß. Here we also found that upon treatment with 150 nM Aß42 for 1 
hour, the p-cofilin/cofilin level in primary neurons dropped to 67.5 ± 8.1 % the value seen in 
cells treated with vehicle alone (Fig. 6e). When pre-treated with 3 μM ALI6, the p-cofilin/
cofilin level was restored to 101.5 ± 7.4 % relative to vehicle treated cells. These results 
indicate ALI6 protects neurons from Aß-induced changes in the cofilin signaling pathway, 
and further support the therapeutic potential of ALI6.
DISCUSSION
Our interaction assays confirm previous reports that LilrB2 recognizes Aß oligomers26, and 
suggest a molecular mechanism for the specificity of recognition. We first mapped the 
binding core to the segment 16KLVFFA21 of Aß and tested two binding epitopes: a tandem 
repeat of 16KLVFFA21 (Aß16–21-TR) designed to spontaneously self-assemble into an anti-
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parallel ß-sheet, and a single copy peptide (Aß16–21-C), which we presume remains single 
stranded in solution under the conditions tested due to an entropy barrier to oligomer 
formation. We found that LilrB2 binds to the tandem repeat but not to the single strand (Fig. 
1), suggesting that LilrB2 recognizes an antiparallel ß-sheet conformation specific to Aß 
oligomers31.
Several lines of evidence support our hypothesis that Aß16–21-TR is a better mimic of the 
full-length Aß oligomer than is Aß16–21-C. Aß16–21-TR has more ß strand content than 
Aß16–21-C as indicated by a higher ellipticity (CD) value measured at 200 nm for the 
peptides linked to the 5x arginine tag (this tag was needed to achieve sufficient solubility) 
(Supplementary Fig. 2, Supplementary Table 1). The analysis of CD spectra also shows that 
the ß strand (antiparallel) content of Aß16–21-TR is higher (33%) than that of Aß16–21-C 
(28%). Moreover, when incubated at 37 °C at high concentration (2 mM), Aß16–21-TR 
formed fibers but Aß16–21-C did not (Supplementary Fig. 2). Presuming that fibrillar and 
oligomeric species share common structural features, these results suggest that Aß16–21-TR 
better mimics the full length Aß oligomer and explain our observation that it is a better 
epitope for LilrB2. Finally, the Rosetta docking experiments using as input the steric zipper 
structure of KLVFFA successfully generated a model that agrees with our LilrB2-
benzamidine complex structure within the top 0.1% of Rosetta energy rankings. These 
results support our previous hypothesis that that ß-sheets are not only characteristic of 
amyloid fibers38 but also of oligomers39,40.
The transient and heterogeneous nature of Aß oligomers makes their structural elucidation 
extremely challenging. The observation that LilrB2 binds to Aß oligomers with a wide range 
of sizes (Supplementary Fig. 2) also indicates the difficulty of characterizing the structure of 
an Aß oligomer-LilrB2 complex. To gain insights into the structure of this complex, we first 
narrowed the binding core of Aß to a six-residue segment (16KLVFFA21), and identified its 
binding site on LilrB2 through the structure of LilrB2 with a small molecule that mimics 
phenylalanine sidechains of the Aß binding core. The binding sites were validated by 
mutagenesis and Rosetta docking, and then used for structure-based inhibitor design. Our 
results show that the LilrB2 D1D2-benzamidine complex structure we determined provides a 
platform sufficient for inhibitor development of the Aß-LilrB2 interaction.
In addition to LilrB2, other putative Aß receptors have been reported to bind Aß oligomers 
and cause neuronal damage25. Our rationale for choosing LilrB2 as a target for inhibitor 
design is that an animal model shows that mice lacking PirB (the murine homolog of LilrB2) 
are immune to the damaging effects of Aß in hippocampal long-term potentiation (LTP) and 
memory26. One reason to suppose that blocking only the LilrB2 receptor might be sufficient 
to inhibit Aß toxicity is that blockade of one high-affinity Aß receptor may sufficiently 
reduce the contact of Aß with cells. This hypothesis is supported by the observation that 
Aß42 oligomer binding to cultured cortical neurons from PirB−/− mice is diminished by 
about 50% relative to wild-type neurons26. In AD patients, this reduction may be sufficient 
to move the equilibrium from Aß-cell contact to Aß clearance41, thus inhibiting Aß triggered 
neuronal toxicity. Our cell viability assays on primary neurons support this hypothesis, 
which show ALI6 can almost completely block the effect of Aß (Fig. 6d). Further study is 
required to identify the possibility that our inhibitor can also work on other Aß receptors.
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Compared to other AD drug development strategies that target Aß aggregation (e.g.15–17) or 
bind monomeric Aß with antibody42, targeting Aß oligomer is advantageous because the 
inhibitor does not need to be added before Aß aggregation. When testing the inhibition of 
Aß cytotoxicity, Aß monomer or aggregation targeting inhibitors need to be co-incubated 
with Aß from the beginning of Aß aggregation (e.g.15); therefore, presumably these 
inhibitors can only treat early-stage AD patients before massive Aß aggregation forms. This 
may be part of the reason why solanezumab, an antibody targeting monomeric Aß failed in 
recent clinical trial43. In comparison, all of our inhibition experiments were done by 
separately adding inhibitors and pre-formed Aß oligomer, offering the possibility of treating 
patients that already have Aß aggregation in their brains.
Structure-based approach has been shown to be a powerful tool for drug development (e.g.
5,44). In this study, we computationally identified 12 candidate inhibitors by structure-guided 
selection. Nine out of 12 candidates show inhibition of Aß-LilrB2 interaction in vitro; 6 
candidates were selected for further testing, and all of them exhibit low micro molar to high 
nanomolar Ki and IC50 values. These inhibitors eliminate the effects of Aß-LilrB2 binding 
on the cell surface, and candidate ALI6 inhibits Aß binding and cytotoxicity to primary 
neurons. Our results support the hypothesis that blocking this Aß-receptor interaction is a 
potential way to inhibit Aß toxicity and prevent neuron damage, and that LilrB2 is a 
promising therapeutic target. In addition, the compound library we used for computational 
inhibitor selection is composed of approved drugs, drugs in animal tests and clinical trials, 
and natural products whose pharmacokinetic (PK) and/or toxicity profile is known. During 
the inhibitor selection process, we also checked the potential of the selected compounds to 
cross the blood-brain barrier (BBB, Supplementary Table 3). This strategy ensures our 
selected inhibitors, e.g. ALI6, are safe for human use and are able to cross the BBB. These 
properties make these inhibitors useful tools in further investigation of the role of LilrB2 in 
pathogenesis of AD and qualifies them as promising candidates for expediting further AD 
drug development. We also note that concentrations of inhibitors we used are high and might 
be difficult to achieve in vivo. Our proof-of-concept study provides several promising 
starting points for drug development, and further work is needed to improve the affinity of 
these inhibitors to increase their translational values.
METHODS AND MATERIALS
Methods and materials used in this study are available in supplementary information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The 16KLVFFA21 segment of Aß binds to LilrB2 D1D2.
ELISA-based interaction assays of Aß42 and its constituent segments. LilrB2 D1D2 (black 
bars) or bovine serum albumin as a negative control (BSA, white bars) was immobilized on 
ELISA plates, and incubated with Aß segments at concentrations shown. The unbound 
segments were washed off and the amounts of bound Aß segments were measured by the Aß 
specific antibody 6E10 and quantified by absorbance at wavelength 450 nm (OD450, left 
panel), or measured by the fluorescence signal of fluorescein (FITC) conjugated to the 
amino-termini of the segments and quantified by fluorescence units (right panel). Notice that 
for Aß1–42, Aß1–21 and Aß16–21-TR, the amounts of Aß segments bound to LilrB2 D1D2 
were significantly higher than that to BSA, indicating interaction between these segments 
and LilrB2 D1D2. The absence of KLVFFA from the weak binder Aß1–15, as well as its 
presence in the stronger binders Aß1–21, and Aß16–21-TR (sequence 
KLVFFAPDGKLVFFA), indicate 16KLVFFA21 is the key segment of Aß that binds to 
LilrB2. Segment sequences are shown in Supplementary Table 1. Data are means ± SD (n=3 
independent experiments). Two-sided t tests were performed and detailed statistical analyses 
are reported in Supplementary Table 4. *, p<0.05; **, p<0.005; ***, p<0.0005, n.s., not 
significant; conc, concentration.
Cao et al. Page 13
Nat Chem. Author manuscript; available in PMC 2019 April 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Crystal structure of LilrB2 D1D2 complexed with benzamidine.
a, Overview of the structure of LilrB2 D1D2 (shown in surface model, colored by 
hydrophobicity) complexed with benzamidine (Ben 1 to 4, shown in sticks). The chemical 
structure of benzamidine is shown at the top right corner. The black dashed line between 
Ben 3 and Ben 4 represents 7.5 Å. Hydrophobicity ranges from −1.7 (hydrophilic) to +3.7 
(hydrophobic). Notice that the binding pockets of Ben 3 and Ben 4 are located at the groove 
between LilrB2 domains D1and D2, and the groove has an extended hydrophobic surface. b 
and c, detailed interaction of Ben 3 (b) and Ben 4 (c) with LilrB2. LilrB2 is shown as a 
cartoon and the side chains of the residues involved in benzamidine binding are shown as 
sticks. The black dashed lines represent distances between 2.4 Å and 4.8 Å.
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Figure 3. Mutagenesis studies and Rosetta docking validate the Aß binding sites on LilrB2.
a, ELISA-based interaction assays using wild type LilrB2 D1D2 (WT) or designed mutants. 
The same amount of LilrB2 D1D2 WT (blue bars), D36G (red bars), V38W (green bars) and 
N168W (purple bars), as well as bovine serum albumin (BSA, white bars) was immobilized 
on an ELISA plate (loading control see Supplementary Fig. 4), and incubated with Aß1–42 or 
Aß16–21-TR at indicated concentrations. The amounts of bound Aß1–42 were measured by 
antibody 6E10 and quantified by absorbance at wavelength 450 nm (OD450, left panel); the 
amounts of bound Aß16–21-TR were measured by fluorescence signal of fluorescein and 
quantified by fluorescence units (right panel). Data are means ± SD (n=3 independent 
experiments, ***p<0.0005, ANOVA test); conc, concentration. For detailed statistical 
analysis see Supplementary Table 4. b-d, Model of two KLVFFA peptides binding to LilrB2 
D1D2 calculated by Rosetta docking. In this model Phe20 from one KLVFFA chain and 
Phe19’ from another chain bind to Ben 3 (d, left panel) and Ben 4 (d, right panel) pockets 
respectively. Three residues tested in mutagenesis studies (Asp36, Val38 and Asn168) were 
used as restraints in Rosetta docking. Residue colors correspond to the key given in panel 
(a).
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Figure 4. Selected small molecules inhibit the Aß-LilrB2 interaction in vitro.
a, immunoprecipitation assays of Aß42 with (black bars) or without (white bar) LilrB2 
D1D2. 1 μM of Aß42 and 100 nM of LilrB2 D1D2 were mixed with 5 μM of Aß-LilrB2 
inhibitors (ALI #1–12) or equal amounts of DMSO (vehicle) and the amount of bound Aß42 
was quantified by ELISA. Data are presented as percentages relative to controls in which 
LilrB2 and vehicle was added. Data are means ± SD (n=3 independent experiments, 
***p<0.0005, ANOVA test). For detailed statistical analysis see Supplementary Table 4. b, 
same immunoprecipitation assays using multiple concentrations of ALI6 (left) and ALI10 
(right). ELISA absorbance values of samples without LilrB2 were subtracted as a 
background from those of samples with LilrB2. The data are presented as percentages 
relative to the samples with LilrB2 and vehicle. The percentage values of samples with 
inhibitors are plotted against the concentration of inhibitors. The name and chemical 
structure of inhibitors is shown on the top of each panel. c, Docking models of ALI6 (upper 
panel) and ALI10 (lower panel) binding to Ben 3 and 4 pockets. Residues involved in 
benzamidine binding are shown as stick models. d, Ki and IC50 values calculated from the 
Cao et al. Page 16
Nat Chem. Author manuscript; available in PMC 2019 April 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
data are shown in (b) and Supplementary Fig. 6. In immunoprecipitation assays shown in (b) 
and (d), data are mean ± SD, n=3 independent experiments.
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Figure 5. Selected inhibitors block LilrB2 induced cell attachment and inhibit toxicity of Aß.
a, Fluorescent images of HEK293T cells transfected with LilrB2-mRFP or mRFP (red), and 
treated with 500 nM fluorescein conjugated to Aß42 (FITC-Aß, green) and 10 μM selected 
Aß-LilrB2 inhibitors (or equal amounts of DMSO as vehicle control). DAPI, 4’, 6-
diamidino-2-phenylindole. b, Quantification of FITC-Aß42 binding represented in (a). Aß42 
binding was quantified as integrated intensity of green fluorescence in each well, normalized 
to LilrB2 expression level quantified as integrated intensity of red fluorescence in the same 
well (or normalized to cell confluency for cells transfect with mRFP), and then presented as 
a percentage relative to the controls, which are LilrB2-mRFP transfected HEK293T cells 
treated with vehicle. Data are means ± SD (n=4 independent experiments, **p<0.005, 
***p<0.0005, ANOVA test). c, Cell viability (MTT) assays show that ALI6 reduces the 
toxicity of Aß42. HEK293T cells transfected with LilrB2-mRFP were treated with indicated 
concentrations of ALI6 or vehicle control, and then 500 nM of oligomeric Aß42 or PBS 
control was added. Cell viability is shown as a percentage relative to controls in which only 
PBS and vehicle are added. Data are means ± SD (n=3 independent experiments, **p<0.005, 
***p<0.0005, ANOVA test). For detailed statistical analysis see Supplementary Table 4.
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Figure 6. Validation of ALI6 using primary neurons.
a, Bright field and fluorescence images of primary neurons treated with 500 nM FITC-Aß 
(green) and 10 μM ALI6 (or equal amounts of DMSO). b, Quantification of FITC-Aß42 
binding represented in (a). Aß42 binding was quantified as integrated intensity of green 
fluorescence in each well, normalized to cell confluency in the same well, and then 
presented as a percentage relative to cells treated with FITC-Aß42 and DMSO (**p<0.005, 
ANOVA test). c, Bright field and fluorescence images of primary neuron cells treated with 
300 nM Aß42 and 5 μM ALI6 or equal amounts of DMSO, or treated with PBS and DMSO 
as vehicle control. Cell viability was measured by TUNEL assays and dead cells are shown 
as red puncta. d, Quantification of TUNEL cell viability assays. Cell viability is shown as a 
percentage of cell death calculated as the number of red puncta divided by the number of 
blue puncta (Hoechst stain) (***p<0.0005, two-sided t test). e, Primary neuron cells were 
treated with 150 nM Aß42 with 3 μM ALI6 or equal amounts of DMSO, and cofilin 
signaling levels were analyzed by Western blotting (left). Anti-Tubulin β−3 antibody detects 
neuronal tubulin and was used as a loading control. Quantification of cofilin phosphorylation 
(right) was calculated as the intensity of phosphorylated cofilin band divided by the intensity 
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of cofilin band, and was normalized to the cells treated with PBS and DMSO (vehicle 
control) (**p<0.005, two-sided t test). All Data are means ± SD (n=4 independent 
experiments). For detailed statistical analysis see Supplementary Table 4.
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